Our results found that elevated ADAMTS14 expression had a higher TIDE score, a higher T-cell dysfunction score, and a lower MSI score, indicating that these patients might have a lower efficacy and worse outcome after accepting the immunotherapy than those ccRCC patients with low expression of ADAMTS14. The gene discussed is ADAMTS14; the disease is nonpapillary renal cell carcinoma.